Click on the company or penalty amount for more information on each case. Click on the current parent name to reach the summary page for that parent company.
Company | Current Parent | Current Parent Industry | Primary Offense Type | Year | Agency | Penalty Amount |
---|---|---|---|---|---|---|
Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2005 | FDA | $36,000,000 |
InterMune Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | FDA | $36,900,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | $71,000,000 |
AstraZeneca | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | KY-AG | $5,500,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | $13,500,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2016 | MULTI-AG | $19,500,000 |
Celgene Corp. | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,700,000 |
Cephalon, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | CT-AG | $6,150,000 |
Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | AR-AG | $18,500,000 |
Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MS-AG | $18,500,000 |
Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | LA-AG | $20,000,000 |
Eli Lilly and Co. | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | CT-AG | $25,100,000 |
Eli Lilly and Co. | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | ID-AG | $13,000,000 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $361,828,456 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $62,000,000 |
Endo Health Solution | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | KY-AG | $3,700,000 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | KY-AG | $661,860 |
Inspire Pharmaceuticals | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,000,000 |
InterMune Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,700,000 |
Janssen Ortho LLC and Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MT-AG | $5,900,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
Novartis Pharmaceuticals | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | TX-AG | $6,638,250 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,681,516 |
Par Pharmaceutical Companies Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,500,000 |
Pfizer | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $35,000,000 |
Purdue Pharma | Purdue Pharma | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | MULTI-AG | $19,500,000 |
Warner-Lambert | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2004 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $190,000,000 |
Wyeth Pharmaceuticals, Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $257,400,000 |
E.R. Squibb & Sons LLC | Bristol-Myers Squibb | pharmaceuticals | PCB violation | 2009 | EPA | $8,125 |
Pfizer Pharmaceuticals | Pfizer | pharmaceuticals | PCB violation | 2010 | EPA | $24,650 |
Celgene Corporation | Bristol-Myers Squibb | pharmaceuticals | PCB violation | 2013 | EPA | $6,035 |
EMD Millipore Corporation | Merck KGaA (EMD) | pharmaceuticals | pesticide violation | 2013 | EPA | $2,681,500 |
Advanced Sterilization Products | Johnson & Johnson | pharmaceuticals | pesticide violation | 2012 | CA-DPR | $25,616 |
Pfizer Inc. | Pfizer | pharmaceuticals | pesticide violation | 2012 | CA-DPR | $6,720 |
Schering-Plough Healthcare Products Inc. | Merck | pharmaceuticals | pesticide violation | 2011 | CA-DPR | $28,400 |
Abbott Laboratories Diagnostics | Abbott Laboratories | pharmaceuticals | pesticide violation | 2007 | CA-DPR | $9,476 |
Hoechst AG | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | DOJ_ANTITRUST | $12,000,000 |
Merck KgaA | Merck KGaA (EMD) | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | DOJ_ANTITRUST | $14,000,000 |
Abbott Laboratories | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2005 | MULTI-AG | $15,350,000 |
Abbott Laboratories | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2010 | MULTI-AG | $22,500,000 |
Alpharma, Inc. | Pfizer | pharmaceuticals | price-fixing or anti-competitive practices | 2004 | MULTI-AG | $750,000 |
Amphastar Pharmaceuticals, Inc. | Amphastar Pharmaceuticals | pharmaceuticals | price-fixing or anti-competitive practices | 2015 | MA-AG | $325,000 |
Aventis Pharmaceuticals, Inc. | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2012 | MULTI-AG | $1,650,000 |
Barr Pharmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2008 | MULTI-AG | $5,900,000 |
Bausch & Lomb | Bausch Health | pharmaceuticals | price-fixing or anti-competitive practices | 2001 | MULTI-AG | $17,500,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $55,000,000 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2008 | MULTI-AG | $1,100,000 |
CIBA Vision | Novartis | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $5,000,000 |
Daiichi Pharmaceutical | Daiichi Sankyo | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $4,340,100 |
Daiichi Pharmaceutical | Daiichi Sankyo | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | CA-AG | $1,446,700 |
Daiichi Pharmaceutical | Daiichi Sankyo | pharmaceuticals | price-fixing or anti-competitive practices | 2002 | MA-AG | $111,167 |
Eisai | Eisai | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $7,634,700 |
Eisai Co. | Eisai | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | CA-AG | $2,544,900 |
Eisai Co. | Eisai | pharmaceuticals | price-fixing or anti-competitive practices | 2002 | MA-AG | $111,167 |
Endo International plc | Endo International | pharmaceuticals | price-fixing or anti-competitive practices | 2019 | MULTI-AG | $2,300,000 |
Geneva Pharmaceuticals | Novartis | pharmaceuticals | price-fixing or anti-competitive practices | 2005 | MULTI-AG | $15,350,000 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | price-fixing or anti-competitive practices | 2006 | MULTI-AG | $14,000,000 |
GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | price-fixing or anti-competitive practices | 2006 | MULTI-AG | $3,500,000 |
Hoffman-LaRoche | Roche | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $142,494,000 |
Hoffman-LaRoche | Roche | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | CA-AG | $47,498,000 |
Hoffman-LaRoche | Roche | pharmaceuticals | price-fixing or anti-competitive practices | 2002 | MA-AG | $111,167 |
Johnson & Johnson Vision Care, Inc. | Johnson & Johnson | pharmaceuticals | price-fixing or anti-competitive practices | 2001 | MULTI-AG | $60,000,000 |
Merck KGaA | Merck KGaA (EMD) | pharmaceuticals | price-fixing or anti-competitive practices | 2009 | MULTI-AG | $2,275,454 |
Mylan Laboratories et al. | Viatris | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $108,000,000 |
Perrigo Company | Perrigo | pharmaceuticals | price-fixing or anti-competitive practices | 2004 | MULTI-AG | $750,000 |
Ranbaxy Pharmaceuticals, Inc. | Sun Pharmaceuticals | pharmaceuticals | price-fixing or anti-competitive practices | 2014 | NY-AG | $150,000 |
SmithKline Beecham Corp. | GlaxoSmithKline | pharmaceuticals | price-fixing or anti-competitive practices | 2005 | MULTI-AG | $10,000,000 |
Takeda Chemical | Takeda Pharmaceutical | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $17,551,650 |
Takeda Chemical | Takeda Pharmaceutical | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | CA-AG | $5,850,550 |
Takeda Chemical | Takeda Pharmaceutical | pharmaceuticals | price-fixing or anti-competitive practices | 2002 | MA-AG | $111,167 |
Teva Pharmaceuticals USA, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2014 | NY-AG | $150,000 |
UCB Pharma, Inc. | UCB | pharmaceuticals | price-fixing or anti-competitive practices | 2009 | MULTI-AG | $2,275,454 |
Warner Chilcott Holdings | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2007 | MULTI-AG | $5,500,000 |
Sandoz Inc. | Sandoz Group | pharmaceuticals | price-fixing or anti-competitive practices | 2020 | DOJ_ANTITRUST | $195,000,000 |
Apotex Corp. | Apotex Corp. | pharmaceuticals | price-fixing or anti-competitive practices | 2020 | DOJ_ANTITRUST | $24,100,000 |
Abbott Laboratories | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2009 | private lawsuit-federal | $10,000,000 |
Abbott Laboratories | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $9,615,384 |
Actavis Elizabeth LLC | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $1,100,000 |
Actavis Elizabeth LLC | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2020 | private lawsuit-federal | $19,900,000 |
Actavis Mid-Atlantic LLC | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $118,614,000 |
Allergan | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2019 | private lawsuit-federal | $934,903 |
Allergan | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2019 | private lawsuit-federal | $1,003,634 |
Allergan | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2019 | private lawsuit-federal | $806,991 |
Allergan | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2017 | private lawsuit-federal | $15,000,000 |
Allergan Inc. | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2018 | private lawsuit-federal | $3,000,000 |
Allergan, Inc. | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2018 | private lawsuit-federal | $13,450,000 |
American BioScience Inc. | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | private lawsuit-federal | $815,000 |
Amgen Inc. | Amgen | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $9,615,384 |
Amneal Pharmaceuticals LLC | Amneal Pharmaceuticals | pharmaceuticals | price-fixing or anti-competitive practices | 2019 | private lawsuit-federal | $400,000 |
Astellas Pharma US, Inc. | Astellas Pharma | pharmaceuticals | price-fixing or anti-competitive practices | 2016 | private lawsuit-federal | $13,250,000 |
AstraZeneca | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2007 | private lawsuit-federal | $24,000,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $11,000,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2012 | private lawsuit-federal | $20,000,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $13,000,000 |